Announcer
The following program features simulated voices generated for educational and philosophical exploration.
Vera Castellanos
Good afternoon. I'm Vera Castellanos.
Ryan Nakamura
And I'm Ryan Nakamura. Welcome to Simulectics Radio.
Vera Castellanos
Today we're examining chimeric antigen receptor T-cell therapy—CAR-T—a form of immunotherapy that genetically engineers a patient's own immune cells to target cancer. T cells are extracted, modified to express synthetic receptors that recognize tumor antigens, expanded in culture, then reinfused. These engineered cells persist in the body, providing potentially durable responses to malignancies that resist conventional treatment. CAR-T represents a fundamental shift from treating cancer with external agents to reprogramming the immune system itself.
Ryan Nakamura
It's the immune system as programmable weapon. We've spent decades trying to poison cancer faster than we poison the patient—chemotherapy's central challenge. CAR-T flips the paradigm. Instead of flooding the body with cytotoxic drugs, we turn the patient's T cells into precision-guided missiles that hunt malignant cells while leaving healthy tissue intact. At least in theory.
Vera Castellanos
Our guest is Dr. Carl June, immunologist at the University of Pennsylvania, whose laboratory developed the first FDA-approved CAR-T therapy for acute lymphoblastic leukemia. His work has established CAR-T as standard treatment for certain blood cancers and opened pathways toward solid tumor applications. Dr. June, welcome.
Dr. Carl June
Thank you. Pleased to be here.
Ryan Nakamura
Let's start with mechanism. How do you engineer T cells to recognize cancer?
Dr. Carl June
Natural T cells recognize targets through T-cell receptors that bind peptides presented on MHC molecules. This limits what they can target. CAR-T cells bypass this restriction. We engineer a chimeric antigen receptor—combining an antibody-derived binding domain with T-cell activation machinery. The binding domain recognizes a surface protein on cancer cells, independent of MHC presentation. When the CAR binds its target, the T-cell activates, proliferates, and kills the cancer cell. We deliver the CAR gene using viral vectors—typically lentivirus—that integrate into the T-cell genome. The modified cells are expanded to therapeutic doses, then infused back into the patient.
Vera Castellanos
What targets have proven most effective for CAR-T therapy?
Dr. Carl June
CD19 has been the most successful target—a protein expressed on B cells and B-cell malignancies like acute lymphoblastic leukemia and diffuse large B-cell lymphoma. CD19 CAR-T therapy produces complete remission in up to eighty percent of patients with relapsed or refractory ALL. The trade-off is B-cell aplasia—normal B cells are also eliminated, requiring immunoglobulin replacement. BCMA, expressed on plasma cells, is effective for multiple myeloma. We're exploring other targets for different cancers, but finding tumor-specific antigens remains challenging. Ideal targets are highly expressed on cancer cells, absent on critical normal tissues, and functionally important to the tumor so it can't easily downregulate the antigen to escape.
Ryan Nakamura
Why has CAR-T worked so well in blood cancers but struggled with solid tumors?
Dr. Carl June
Several barriers. First, antigen heterogeneity—solid tumors express diverse antigens, and targeting one allows antigen-negative cells to escape. Blood cancers are more homogeneous. Second, trafficking—CAR-T cells must penetrate solid tumors, which they often fail to do efficiently. Third, the tumor microenvironment is immunosuppressive—hypoxic, acidic, filled with regulatory T cells and myeloid-derived suppressor cells that inhibit CAR-T function. Fourth, on-target, off-tumor toxicity—many solid tumor antigens are also expressed at low levels on normal tissues, causing damage when CAR-T cells attack. We're addressing these through combinatorial targeting, armoring CAR-T cells against immunosuppression, and engineering conditional activation systems.
Vera Castellanos
Let's discuss toxicity. CAR-T therapy can trigger severe, sometimes fatal immune reactions. What are the mechanisms and how are they managed?
Dr. Carl June
The primary toxicity is cytokine release syndrome—CRS. When CAR-T cells encounter tumor antigen and activate en masse, they release inflammatory cytokines like IL-6, IFN-gamma, and TNF-alpha. This can cause high fever, hypotension, organ dysfunction, and in severe cases, multi-organ failure. We manage CRS with tocilizumab, an IL-6 receptor antagonist, and corticosteroids if needed. The second major toxicity is neurotoxicity—immune effector cell-associated neurotoxicity syndrome, or ICANS. Mechanisms aren't fully understood but involve cytokine effects on the blood-brain barrier and direct CNS inflammation. Symptoms range from confusion and aphasia to seizures and cerebral edema. Most cases resolve, but some are fatal. We monitor patients closely in specialized centers equipped to manage these complications.
Ryan Nakamura
How do you balance efficacy and safety when engineering CARs? More potent activation might increase tumor killing but also toxicity.
Dr. Carl June
Exactly. Early CARs had first-generation signaling—just CD3-zeta activation. Second-generation CARs added a costimulatory domain—4-1BB or CD28—improving persistence and efficacy but increasing CRS risk. We now engineer controllable systems. Suicide genes allow us to eliminate CAR-T cells if toxicity becomes unmanageable. Split CARs require two antigens for full activation, reducing off-tumor toxicity. Inducible CARs activate only in the presence of a small molecule drug, giving temporal control. We're also tuning CAR affinity—lower affinity reduces on-target, off-tumor toxicity while maintaining anti-tumor efficacy if the tumor expresses high antigen levels. It's a balancing act between therapeutic window and side effect profile.
Vera Castellanos
What about allogeneic CAR-T—using donor cells instead of the patient's own? That could reduce cost and turnaround time.
Dr. Carl June
Autologous CAR-T requires individualized manufacturing—expensive, time-consuming, and sometimes unsuccessful if the patient's T cells are dysfunctional from prior chemotherapy. Allogeneic CAR-T from healthy donors could be manufactured at scale and stored as off-the-shelf product. The challenge is preventing graft-versus-host disease, where donor T cells attack the patient's tissues. We address this by disrupting the T-cell receptor using gene editing—CRISPR or TALEN—so the CAR-T cells can't recognize MHC mismatches. We also disrupt beta-2-microglobulin to prevent rejection by the patient's immune system. Early trials show feasibility, but allogeneic CAR-T cells persist less than autologous, possibly due to immune rejection despite gene editing. We're working on improving persistence and efficacy.
Ryan Nakamura
Could CAR-T be applied beyond cancer? Autoimmune diseases, chronic infections, senescent cells?
Dr. Carl June
Absolutely. We're exploring CAR-T for autoimmune diseases like lupus and myasthenia gravis by targeting autoreactive B cells. Early results are promising—CD19 CAR-T depletes pathogenic B cells, inducing remission in severe cases. For chronic infections, we could engineer CAR-T cells to target infected cells. The challenge is distinguishing infected from uninfected cells. Senescent cell clearance is conceptually feasible—if we identify surface markers specific to senescent cells, CAR-T could eliminate them. The advantage over small-molecule senolytics is specificity and persistence. CAR-T could provide ongoing surveillance, eliminating senescent cells as they arise. It's speculative but scientifically plausible.
Vera Castellanos
That raises the question of living with engineered cells indefinitely. CAR-T cells can persist for years. What are the long-term risks?
Dr. Carl June
Viral vector integration carries insertional mutagenesis risk—the CAR gene could disrupt a tumor suppressor or activate an oncogene, potentially causing leukemia. We've seen rare cases in gene therapy trials. The risk is low with modern vectors, but not zero. Chronic B-cell aplasia from CD19 CAR-T requires lifelong immunoglobulin replacement and monitoring for infections. We don't yet have decades-long safety data. Most CAR-T patients had terminal cancer and limited life expectancy, so long-term risks were acceptable trade-offs. As we move toward earlier-line therapy and non-oncology applications, we need better long-term safety profiles. Non-integrating delivery methods or controlled persistence mechanisms may be necessary.
Ryan Nakamura
What about engineering CAR-T cells with additional functions—cytokine secretion, checkpoint blockade resistance, anti-immunosuppression?
Dr. Carl June
We call these armored CAR-T cells. We can engineer them to secrete IL-12, enhancing anti-tumor immunity, or express dominant-negative PD-1 receptors, preventing checkpoint inhibition. We can disrupt genes that respond to immunosuppressive signals in the tumor microenvironment. We can add chemokine receptors to improve tumor trafficking. The challenge is complexity—each additional modification increases manufacturing difficulty and regulatory burden. We also risk unforeseen interactions between engineered components. Simpler is often better, but as we encounter resistance mechanisms, we'll need these advanced designs. It's iterative—treat patients, identify why therapy fails, engineer solutions, repeat.
Vera Castellanos
How do tumors escape CAR-T therapy?
Dr. Carl June
Several mechanisms. Antigen loss or downregulation—the tumor stops expressing the target. This is common when targeting a single antigen. Antigen-negative clones that were present at low frequency expand after antigen-positive cells are eliminated. T-cell exhaustion—CAR-T cells lose effector function over time, especially in hostile tumor microenvironments. Immunosuppression by the tumor—secretion of adenosine, TGF-beta, or recruitment of Tregs. Tumor-intrinsic resistance—upregulation of anti-apoptotic proteins. We address these through multi-antigen targeting, checkpoint inhibitor combinations, metabolic reprogramming of CAR-T cells, and engineering resistance to exhaustion.
Ryan Nakamura
Could we combine CAR-T with other modalities—oncolytic viruses, radiation, chemotherapy?
Dr. Carl June
Yes. Oncolytic viruses can inflame cold tumors, making them more visible to CAR-T cells and releasing tumor antigens that prime endogenous immunity. Radiation causes immunogenic cell death, similarly enhancing CAR-T efficacy. Chemotherapy can lymphodeplete, eliminating regulatory cells and creating space for CAR-T expansion. We're testing these combinations. The challenge is sequencing and dosing—too much chemotherapy can damage CAR-T cells, while poorly timed virus administration might not synergize. Combination therapy is the future, but requires careful optimization.
Vera Castellanos
What about using CAR-T as prophylaxis in high-risk individuals—preventing cancer before it arises?
Dr. Carl June
That's speculative. We'd need to identify pre-malignant cells with targetable antigens and ensure CAR-T cells don't cause unacceptable toxicity in healthy individuals. The risk-benefit calculation is very different from treating terminal cancer. If we could target cells with oncogenic mutations before they progress, we might prevent cancer. But we lack biomarkers to identify who would benefit, and prophylactic use raises ethical questions—subjecting healthy people to risks of gene therapy and chronic immune modulation. It's not near-term, but conceptually possible if we achieve safer, more controllable CAR-T platforms.
Ryan Nakamura
Let's discuss cost. CAR-T therapy costs hundreds of thousands of dollars. How do we make this accessible?
Dr. Carl June
Cost reflects individualized manufacturing, specialized facilities, and inpatient monitoring for toxicity management. Allogeneic CAR-T reduces manufacturing cost through economies of scale. Automated closed-loop manufacturing systems reduce labor and contamination risks. Outpatient management for low-risk patients reduces hospitalization costs. Gene editing technologies like CRISPR make allogeneic CAR-T more feasible. We also need regulatory frameworks that don't require repeating expensive trials for minor modifications. Ultimately, widespread adoption will drive costs down, as happened with monoclonal antibodies. But access remains a major challenge, especially in low-resource settings.
Vera Castellanos
Looking forward, what are the next frontiers?
Dr. Carl June
Solid tumor efficacy is the major challenge. If we crack that, CAR-T becomes relevant for the majority of cancers. We're also pursuing in vivo CAR-T—delivering CAR genes directly into the patient's T cells without extraction, using lipid nanoparticles or viral vectors. This would eliminate manufacturing delays and costs. Multi-antigen CARs prevent escape. Logic-gated CARs—requiring multiple signals for activation—improve specificity. Universal CARs that can be redirected to different targets using adapter molecules offer flexibility. And moving beyond T cells—engineering NK cells, macrophages, or other immune cells with CARs broadens the toolkit. The field is rapidly evolving.
Ryan Nakamura
Which brings us to the philosophical question. If we can reprogram immune cells to target cancer, what else can we reprogram them to target?
Dr. Carl June
Anything with a targetable surface marker. The immune system evolved to distinguish self from non-self. We're hacking that machinery to redefine threats. The power is enormous, but so is the responsibility. Engineering immune cells to attack pathogens, senescent cells, or misfolded proteins could extend healthspan. But the same technology could be misused—targeting healthy cells in malicious applications. We need robust oversight, ethical guidelines, and public engagement to ensure these technologies benefit humanity without creating new risks.
Vera Castellanos
Which requires humility about what we're unleashing when we reprogram fundamental biological systems.
Ryan Nakamura
And vigilance about who controls access to these capabilities.
Vera Castellanos
Dr. June, thank you for this discussion.
Dr. Carl June
My pleasure. Thank you.
Ryan Nakamura
Tomorrow we examine synthetic biology and programmable organisms with Dr. George Church.
Vera Castellanos
Until then. Good afternoon.